baber/WOPTO huggingface dataset:
Patent NZ-586781-A (NZ)
Title: Therapeutic heparins and their binding to interleukins 4
Inventor: COOMBE DEIRDRE ROMA
IPC: A61P31/04
Filed: 2005-04-19
Abstract: Disclosed is a method for identifying an antagonist of interleukin-4 comprising the steps of: (i) immobilizing IL-4 to a solid support; (ii) (ii) generating a fraction of heparin and identifying the heparin fraction which binds to IL-4 at a location on IL-4 defined by amino acids K12, R53, K61, H74, R75,K77, R81, R84, R85 and R88; (iii) Selecting the identified fraction of non-full length heparin from (ii) and screening for a compound which prevents binding of that fraction to the immobilized IL-4; (iv) Subjecting the compounds identified in (iii) to an assay to determine whether it antagonizes IL-4 activity; (v) Selecting the compound from (iv) which antagonizes IL-4 activity. (62) Divided Out of 550715
Patent NZ-587004-A (NZ)
Title: Heterocyclic containing entities, compositions and methods
Inventor: WILSON TROY EDWARD
IPC: A61K31/4375
Filed: 2009-01-05
Abstract: 587004 Disclosed are isoquinolin-1(2H)-one, naphthyridin-5(6H)-one, 3,4-dihydroisoquinolin-1(2H)-one and analogues thereof as represented by the general formula (I), or a pharmaceutically acceptable salt thereof, wherein Wa1 is CR3 or N; Wa2 is CR5 or N; Wa3 is CR6 or N; Wa4 is CR7 or N; Wb5 is CR8 or CHR8, wherein no more than two adjacent ring atoms selected from Wa1, Wa2, Wa3, Wa4, and Wb5 are heteroatoms; Wd is a heteroaryl selected from the group consisting of: 6-amino-9H-purin-9-yl, 4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl, or 4-amino-1H-pyrazolo[4,3-c]pyridin-1-yl, wherein the heteroaryl is optionally substituted; B is alkyl, amino, heteroalkyl, cycloalkyl, heterocycloalkyl, or an optionally substituted monocyclic aryl, heteroaryl, heterocycloalkyl, or cycloalkyl ring system, X is absent or is -(CH(R9))z-; Y is absent, -O-, -S-, -S(=O)-, -S(=O)2-, -N(R9)-, -C(=O)-, -N(R9)-C(=O)-, or -N(R9)-C(=O)NH-,-N(R9)C(R9)2-, or -C(=O)-(CHR9)z-; and wherein the remaining substituents are as defined herein. Representative compounds include 3-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-8-methyl-2-o-tolylisoquinolin-1(2H)-one, 3-((6-amino-9H-purin-9-yl)methyl)-8-methyl-2-o-tolylisoquinolin-1(2H)-one, 3-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-2-isopropyl-8-methylisoquinolin-1(2H)-one, 7-((4-amino-3-(3-hydroxyphenyl)- 1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-4-methyl-6-o-tolyl-1,6-naphthyridin-5(6H)-one and 3-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-8-methyl-2-o-tolyl-3,4-dihydroisoquinolin-1(2H)-one. Further disclosed is a composition comprising a pharmaceutically acceptable excipient and a compound as defined above, for use in treating of a disorder chosen from one or more of cancer, bone disorder, inflammatory disease, immune disease, nervous system disease, metabolic disease, respiratory disease, thrombosis, or cardiac disease, including inflammatory or an autoimmune disease, a respiratory disease, asthma, emphysema, allergy, dermatitis, rheumatoid arthritis, osteoarthritis, inflammatory bowel diseases, chronic obstructive pulmonary disorder, psoriasis, multiple sclerosis, disorders related to diabetic complications, lupus erythematosus, scleroderma, graft versus host disease, etc..
Patent NZ-592323-A (NZ)
Title: Method and system for controlled infusion of therapeutic substances
Inventor: MOUBAYED AHMED-MAHER
IPC: G16H20/17
Filed: 2007-09-18
Abstract: An infusion system for determining the infusion profile having a number of infusion steps for infusing an infusate into the body of a human or animal subject is disclosed. The system comprises a programmable controller and a pump and the system operates by the steps of A) assigning to the controller the following parameters i) total infusate volume; ii) total number of infusion steps; iii) time duration per infusion step, iv) maximum infusion rate, v) initial infusion rate, vi) incremental increase in infusion rate and vii) ramp rate; B) the controller calculating a first infusion step having i) a ramping segment wherein the infusion rate increases at the assigned ramp rate from zero to the assigned initial infusion rate and ii) a terminal segment; C) the pump co-operating with the controller to perform the first infusion step with the infusion continuing at approximately the assigned initial infusion rate until the assigned time duration has been reached; D) the controller calculating a volume of infusate delivered during the preceding infusion step; E) the controller calculating the remaining volume of infusate to be infused to deliver the assigned total infusate volume; F) the controller calculating an additional infusion step based on the remaining volume of infusate to be infused and the volume of infusate delivered during the preceding infusion step, the additional infusion step having: i) a ramping segment wherein the infusion rate increases at the assigned ramp rate from the infusion rate of the terminal portion of the preceding infusion step to a new infusion rate that is equal to the infusion rate of the terminal portion of the preceding infusion step plus the incremental increase in infusion rate with the new infusion rate not exceeding the assigned maximum infusion rate and ii) a terminal segment; G) the pump co-operating with the controller to perform the additional infusion step wih the infusion continuing at approximately the new infusion rate until the assigned time duration or the assigned total infusate volume has been reached; and H) repeating Steps D through G until the assigned total infusate volume has been delivered.
Patent NZ-593617-A (NZ)
Title: Nucleic acids and proteins from streptococcus groups A & B
Inventor: TELFORD JOHN
IPC: A61K39/00
Filed: 2001-10-29
Abstract: Disclosed are nuclieic acid sequences and proteins derived from Streptococcus groups A and B. Specifically S. pyrogenes or S. agalactiae. Further disclosed are methods and kits for identifying and extracting the disclosed sequences and proteins.
Patent NZ-594087-A (NZ)
Title: Novel method for the synthesis of ivabradine and the pharmaceutically acceptable acid addition salts thereof
Inventor: PEGLION JEAN-LOUIS
IPC: A61K31/55
Filed: 2010-02-03
Abstract: Disclosed herein is a process for the synthesis of the compound formula (VI)   preferably ivabradine (3-{ 3-[{ [(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl} (methyl)amino]-propyl} -7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one), in its racemic or optically active form, characterised in that the compound of formula (VII), in racemic or optically active form, is subjected to an alkylation reaction with the compound of formula (VIII) in the presence of a base and an organic solvent.
Patent NZ-596297-A (NZ)
Title: Biodegradable implants with hydrophobic coating for the treatment of dopamine associated states
Inventor: SEBREE TERRI B
IPC: A61K31/517
Filed: 2011-11-09
Abstract: ABSTRACT - 596297 The disclosure relates to a use of a biocompatible and/or biodegradable polymer and an effective amount of a dopamine modulating compound in the manufacture of a biodegradable implant for treating a subject for a dopamine associated state, wherein said dopamine modulating compound is a dopamine agonist selected from the group consisting of apomorphine, lisuride, pergolide, bromocriptine, pramipexole, rotigotine, docarpamine, terguride, cabergoline, levodopa, spheramine, romergoline, carmoxirole, zelandopam, sumanirole, sibenadet, a 4-alkylamino-2(3H)-indolone compound, a compound of formula (I), ropinrole, and any combination thereof, wherein R is amino, alkylamino, di-alkylamino, alkenylamino, dialkenylamino, N-alkyl-N-alkenylamino, benzylamino, dibenzylamino, aryl alkyl amino , or diarylalkylamino; R1, R2 and R3 are each independently hydrogen or alkyl; and n is 1, 2, or 3, or a pharmaceutically acceptable salt thereof; wherein said implant comprises a hydrophobic coating comprising one or more hydrophobic polymers selected from the group consisting of polyglycolide (PLGA), polycapralactone (PCL), poly-L-lactic acid (PLA), ethylcellulose, and copolymers thereof, and wherein said dopamine associated state is Parkinson's disease, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism, pervasive development disorder (PDD), Asberger's syndrome, toxin- induced parkinsonism, disease-induced parkinsonism, erectile dysfunction, restless leg syndrome, or hyperprolactinemia.
Patent NZ-600426-A (NZ)
Title: Water swellable polymer materials
Inventor: BAKER MATTHEW PAUL
IPC: C09B69/10
Filed: 2010-12-01
Abstract: Disclosed herein is a method of preparing an aqueous dispersion of polymer encapsulated particulate material, the method comprising: providing a dispersion of the particulate material in a continuous aqueous phase, the dispersion comprising RAFT agent as a stabiliser for the particulate material; and polymerising ethylenically unsaturated monomer under the control of the RAFT agent to form polymer at the surface of the dispersed particulate material, thereby providing the aqueous dispersion of polymer encapsulated particulate material; wherein polymerisation of the ethylenically unsaturated monomer comprises: (a) polymerising a monomer composition that includes ionisable ethylenically unsaturated monomer so as to form a base responsive water swellable RAFT polymer layer that encapsulates the particulate material; and (b) polymerising a monomer composition that includes non-ionisable ethylenically unsaturated monomer so as to form an extensible, water and base permeable RAFT polymer layer that encapsulates the base responsive water swellable RAFT polymer layer.
Patent NZ-602169-A (NZ)
Title: Wind turbine system
Inventor: RODWAY GILES HENRY
IPC: F03D1/02
Filed: 2011-03-03
Abstract: 602169 Disclosed is a system for capturing energy from the wind. The system includes a plurality of modules such that each of the modules includes one or more electrically conductive structural rails (1a), a wind turbine (2), supported by of the electrically conductive structural rails (1a) and an electrical generator (4), driven by the wind turbine (2). The electrical generator (4) includes at least a first electrical terminal which is electrically connected to at least a first of the electrically conductive structural rails (1a), and at least a second electrical terminal which is electrically connected to a separate electrical conductor that is electrically isolated from the first electrically conductive structural rail (1a). The modules are electrically linked to one another such that each of the first electrically conductive structural rails (1a) is electrically connected to the electrically equivalent electrically conductive structural rail (1b) on an adjacent module such that the linked array of modules includes a line of concatenated electrically conductive structural rails. The line of concatenated electrically conductive structural rails together with the electrical conductor(s) are capable of conveying electrical energy from the wind turbine generators to a chosen location or locations for consumption, storage, or onward transmission of the electrical energy.
Patent NZ-616823-A (NZ)
Title: Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response
Inventor: NOWILL ALEXANDRE EDUARDO
IPC: A61P37/04
Filed: 2012-03-19
Abstract: Discloses immunogenic compositions for preventing and/or treating disease in a human or animal comprising a therapeutically effective amount of three or more either natural or synthetic antigen agents comprising pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) or groups thereof selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (B) antigenic agents with molecular patterns associated with viruses; (C) antigenic agents with molecular patterns associated with fungi and yeasts; (D) antigenic agents with molecular patterns associated with protozoa; (E) antigenic agents with molecular patterns associated with helminths and/or (F) antigenic agents with molecular patterns associated with prions wherein the concentration of each agent is within the range 0.001 to 500 micrograms per ml and the composition further comprises one or more physiologically acceptable carriers, excipients, diluents or solvents.
Patent NZ-617117-A (NZ)
Title: Process for treating microfibrillated cellulose and microfibrillated cellulose treated according to the process
Inventor: HEISKANEN ISTO
IPC: D21H11/18
Filed: 2012-05-11
Abstract: Process for removing liquid from a slurry comprising microfibrillated cellulose comprises providing a slurry comprising microfibrillated cellulose and liquid, subjecting the slurry to an electric field inducing the liquid of the slurry to flow and separating the liquid from the microfibrillated cellulose.
Patent NZ-622483-A (NZ)
Title: Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
Inventor: HOOD JOHN
IPC: C07D413/12
Filed: 2012-09-13
Abstract: Provided are indazole-3-carboxamide derivative compounds of the general formula (I), wherein the variables are as defined in the specification. Examples of the compounds include 5-(Pyridin-3-yl)-N-(pyridin-4-yl)-1H-indazole-3-carboxamide and N-(6-carbamoylpyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide. The compounds are Wnt/β-catenin signalling pathway inhibitors and may be useful in the treatment of various diseases associated with the aforementioned pathway including cancer.
Patent NZ-622909-A (NZ)
Title: Composition and method for the protection of articular cartilage
Inventor: NAGABHUSHANAM KALYANAM
IPC: A61K31/216
Filed: 2014-01-10
Abstract: Disclosed is the therapeutic potential of Calebin A (Feruloylmethyl Ferulate) and compositions thereof to prevent pathological damage to mammalian articular cartilage. Specifically a method has been provided for protecting mammalian articular cartilage from pathological damage, said method comprising the step of administering effective dose of Calebin A to mammals in need of said protection.
Patent NZ-623319-A (NZ)
Title: Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
Inventor: THUDIUM KENT B
IPC: C07K17/00
Filed: 2009-08-11
Abstract: Disclosed is an isolated monoclonal antibody, or an antigen-binding portion thereof, which binds human LAG-3, wherein the antibody comprises heavy and light chain variable region sequences having at least 80% amino acid sequence homology to SEQ ID NOs: 37 and 43, respectively. Further disclosed is an isolated monoclonal antibody, or an antigen-binding portion thereof, which binds human LAG-3, wherein the antibody comprises heavy chain variable region CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 1, 7, and 13, respectively, and light chain variable region CDR1, CDR2, and CDR3 sequences as set forth in SEQ ID NOs: 19, 25, and 31, respectively.
Patent NZ-702186-A (NZ)
Title: Producing edible residues from ethanol production
Inventor: MEDOFF MARSHALL
IPC: A23K10/38
Filed: 2010-10-12
Abstract: Disclosed is a method for producing irradiated edible residues comprising: irradiating edible residues that have been produced as a by-product of an ethanol manufacturing process that utilizes a cellulosic or lignocellulosic feedstocks, wherein the edible residues comprise undigested cellulose, and the ethanol manufacturing process includes reducing the recalcitrance of the cellulosic or lignocellulosic feedstock.
Patent NZ-713589-A (NZ)
Title: Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
Inventor: Štursa Jan
IPC: C07F9/54
Filed: 2014-04-07
Abstract: The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n = 6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and/or IA or their corresponding salts of tertiary amine.
Patent NZ-718014-A (NZ)
Title: Deformable container and dispensing machine
Inventor: GAMBURG ROMAN
IPC: B65D85/78
Filed: 2014-09-02
Abstract: A deformable container for single serving of a viscous or semi-solid product from an associated dispensing machine, the deformable container having a cylindrical or conical shape with two opposing end walls and at least one collapsible side wall connecting the first and second end walls, wherein one end wall is provided an opening with a cover through which the product is dispensed from the container. The collapsible side wall may have a cylindrical shape with a plurality of pleats arranged in an accordion-like shape, and be configured to collapse on itself into a substantially flattened position while maintaining a vertical alignment of each pleat. Upon extrusion of a dispensable product from the deformable container the collapsible side wall is configured to collapse into a locked configuration reducing the volume of space occupied by the deformable container, thereby reducing pollution.
Patent NZ-718118-A (NZ)
Title: 4-{ 4-[(1e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl} -5-(propan-2-yl)-1h-pyrazol-3-yl beta-d-glucopyranoside acetate
Inventor: REUTZEL-EDENS SUSAN MARIE
IPC: C07H17/02
Filed: 2014-10-30
Abstract: The present invention provides a compound of Formula I or hydrate thereof, useful for the treatment of diabetes.
Patent NZ-719072-A (NZ)
Title: A foam-based interfacing structure method and apparatus
Inventor: VELISS LEE JAMES
IPC: A62B9/06
Filed: 2009-09-03
Abstract: A facial mask assembly for use in providing a supply of air at pressure to the entrance of the airways of a person, the mask assembly comprising: a frame; a substructure (clip 3234) that is connected to the frame; and a cushion (3232) supported by the substructure, the cushion being formed at least in part from foam. A cross-section in at least one region of the cushion has a base side defined by a base surface of the cushion, an outer side defined by an outer surface of the cushion, the outer surface facing away from a centre of the mask, and an inner side defined by an inner surface of the cushion, the inner surface facing toward the centre of the mask, the outer side and the inner side extending away from the base side and intercepting each other at an apex (3600). The base side is engaged to a support surface of the substructure. In use, the facial mask assembly is structured and/or arranged to create a rolling-in effect in the at least one region in which the cushion rolls inwards towards the centre of the mask on application of force to the cushion by headgear straps so that a portion of the outer surface contacts the face of the patient. The rolling-in effect is created by at least one of: (a) an inner peripheral edge of the support surface being outwardly offset from an inner peripheral edge of the base side; and (b) the outer side being longer than the inner side.
Patent NZ-723092-A (NZ)
Title: Lock devices, systems and methods
Inventor: MCKIBBEN AARON P
IPC: E05B47/06
Filed: 2013-01-30
Abstract: Auto dead bolt door furniture 96 is provided with a first side key entry and a back side user grappling member and includes a motor 80 disposed within the lock, a driver coupler 84 operable to convey torque between the motor and the dead bolt, and a gearing system that includes a plurality of toothed members 92, 94, 98 having corresponding intermeshed gear teeth disposed between the motor and the driver coupler and operable to convey torque from the motor to the driver coupler to actuate the dead bolt. A first of the toothed members such as pinion gear 92 is coupled directly to the motor, and the gears cooperate to permit the motor to be driven backwards by rotation of the user grappling member or a key associated with the key entry to allow torque to be applied to move the plurality of toothed members in a first direction and in an opposite second direction so that the pinion is either a driven gear or a driving gear depending on the torque applied. The drive coupler 84 is set within a hollow in the main gear 98 to effect a lost motion coupling that permits the driver coupler to rotate and actuate the dead bolt without movement of the gear train.
Patent NZ-727708-A (NZ)
Title: System and method of contact identification dissemination
Inventor: KING KEVIN ELLIOTT
IPC: H04L12/66
Filed: 2016-05-31
Abstract: A system and method are presented for contact identification dissemination among devices within a hybrid cloud distributed system. Information associated with a first party device is provided to a cloud managed telephony network appliance. The appliance communicates with a cloud application and is capable of communication with any other appliances which may be associated with a second party device, if that appliance is not already associated with the second party device. Information between the components in the system may be asynchronously updated in order to provide first party information and more granular matches.
Patent NZ-727749-A (NZ)
Title: Use of anti-aging glycopeptides to enhance beta cell health, survival and improve transplant outcome
Inventor: YOUNG LACHLAN GRANT
IPC: C12N5/071
Filed: 2015-06-02
Abstract: The present disclosure relates to an in vitro method for enhancing engraftment of isolated pancreatic cells comprising the step of contacting an isolated pancreatic cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C- glycopeptide compound of general formula (III), or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula III.
Patent NZ-734203-A (NZ)
Title: Prosthesis for improved penis function
Inventor: ELIST JAMES
IPC: A61F2/26
Filed: 2016-03-04
Abstract: A subcutaneous prosthesis subcutaneously implanted within a penis, the prosthesis forming two sides of an elongated cylinder, the sides hinged along top longitudinal edges of their sides. One end of the prosthesis has a gauze sheath providing a means to secure the prosthesis from moving relative to the corpora cavernosa around which it is placed. When the penis is erect it grows in girth thereby causing the two sides of the cylindrical prosthesis to spread divergently and forcing a press-rib against the deep dorsal vein of the penis, thereby restricting blood flow out of the penis so as to improve erectile rigidity and duration. The inventive concept is the pair of moveable edges of the elongate body, this allows the prosthesis to change shape, converging or diverging, depending on whether the penis is erect or flaccid. This provides a more natural appearance whilst also providing sufficient rigidity.
Patent NZ-737616-A (NZ)
Title: Solid forms of a compound modulating kinases
Inventor: IBRAHIM PRABHA
IPC: A61K31/437
Filed: 2016-05-05
Abstract: Solid forms of the compound, [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine HCl salt (Compound I) and its free base, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3, were prepared and characterized. Also provided are methods of using the solid forms.